Juventas wins $22m for regenerative medicine platform
This article was originally published in Scrip
Executive Summary
Juventas Therapeutics raised more than double the seed and grant funding the regenerative medicine company has collected since its founding in 2007 with a $22 million Series B round led by Triathlon Medical Ventures and new investor New Science Ventures.